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Rationale: Epidemiologic studies have shown that exacerbation of
asthma is modulated by environmental endotoxin. High levels of
endotoxinare associated with asthma symptomsand the current use
of asthma medication. However, the underlying mechanisms by
which endotoxin modulates asthma are not completely understood.
Objectives: The aim of the study was to test whether endotoxin
enhances the response of individuals with allergic asthma to aller-
gen, and to determine if this interaction is associated with increased
numbers of antigen-presenting cells in the airways.
Methods: Seventeen subjects with mild allergic asthma underwent
segmental challenge with allergen, endotoxin, and the combination
of both in three different lung segments via bronchoscopy. The
cellular influx including monocytes, myeloid dendritic cells (mDCs),
and plasmacytoid dendritic cells (pDCs), as well as the level of
cytokines, were assessed in bronchoalveolar lavage fluid obtained
24 hours after segmental challenge. Monocytes, mDCs, and pDCs
were isolated and their capacity to induce T cell proliferation was
determined.
Measurements and Main Results: Endotoxin enhanced the cellular
response to allergen. The combination of allergen and endotoxin
resulted in increased numbers of total cells, lymphocytes, neutro-
phils, eosinophils, monocytes, and mDCs, as well as increased levels
of lipopolysaccharide-binding protein, IL-1a, IL-6, and tumor necro-
sis factor–a in the bronchoalveolar lavage fluid compared with
allergen alone. Isolated mDCs but not pDCs induced a strong T cell
proliferation in vitro.
Conclusions: Endotoxin augments the allergic inflammation in the
lungs of individuals with asthma, and induces an enhanced influx of
monocytes and functionally active antigen-presenting mDCs into
the respiratory tract.
Keywords: dendritic cells; monocytes; bronchoalveolar lavage; endo-
bronchial allergen challenge; mixed lymphocyte culture test
Endotoxin is a pro-inflammatory lipopolysaccaride-protein com-
plex (LPS) from the outer membrane of gram-negative bacteria,
which is ubiquitous in the environment. Significant amounts of
endotoxin are detectable in ambient aerosols (2), and it is an
important component of environmental tobacco smoke (3, 4).
The exposure to endotoxin showed heterogeneous effects in
asthma and allergy (5). While it is well established that early life
exposure to endotoxin protects against the development of
allergies (6), it has recently been shown that household endo-
toxin exposure is a significant risk factor for increased asthma
prevalence in adults (7). Higher levels of endotoxin were
significantly associated with the diagnosis of asthma, asthma
symptoms, and the current use of asthma medication. Michel
and coworkers have shown that the severity of asthma is
significantly related to the endotoxin level in the house envi-
ronment, with no association to the mite allergen concentration
(8). Furthermore, it is known that in patients with asthma
inhalation of endotoxin causes a significant decrease in lung
function with an enhanced airway hyperreactivity (AHR) (9,
10). Boehlecke and colleagues (11) confirmed this finding,
demonstrating an increase in AHR to mite allergen when the
subjects were exposed to low-level ambient air endotoxin in an
exposure chamber before inhaled allergen challenge.
Despite the well-documented negative effects of endotoxin
on prevalence and severity of asthma, the underlying mecha-
nism is not completely established. Patients with asthma show
an increase in the eosinophilic nasal inflammation after nasal
exposure to allergen and endotoxin (12). In healthy subjects, the
inhalation of endotoxin skewed airway inflammation in a TH2
direction (13) and increased the maturation of pulmonary
antigen-presenting cells, including dendritic cells (DCs) (14).
However, the degree to which allergic inflammation is modified
in the lower airways of patients with asthma after concomitant
exposure to endotoxin and allergen is not known.
The aim of this study was to further elucidate the mechanism
underlying the pro-inflammatory effect of endotoxin in the
airways of patients with allergic asthma. The well-established
model of segmental allergen challenge was combined with the
endobronchial instillation of endotoxin (15) in subjects with
mild allergic asthma.
We put the main focus of this study on allergen-presenting
cells like monocytes and DCs. In particular, DCs link the innate
and adaptive immune responses (16) and are thus modulators
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Epidemiologic studies have linked exacerbations of asthma
to environmental endotoxin and animal studies, suggesting
that myeloid dendritic cells play a key role in inducing and
maintaining an adaptive immune response to lung aller-
gens.
What This Study Adds to the Field
We have shown in individuals with allergic asthma that
endotoxin augments allergen-dependent allergic airway
inflammation and enhances airway influx of myeloid den-
dritic cells. These data suggest a mechanism by which
endotoxin increases asthma severity.
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of the immune system (17). Pulmonary DCs (18), which mod-
ulate the asthmatic inflammation (17), were recently character-
ized in the human lung (18–22). The functional subset of
myeloid DCs (mDCs) plays a key role in inducing and main-
taining an adaptive immune response to allergens in the lung
(23). This is in contrast to plasmacytoid DCs (pDCs), which
have been identified as important cells in the prevention of
reactions by individuals with asthma to inhaled antigen by the
induction of tolerance (24, 25). Therefore, we isolated and
characterized DC subsets as well as monocytes as potential
precursors of DCs in the human lung.
We hypothesized that concomitant exposure to endotoxin
and allergen would enhance the influx of antigen-presenting
cells like monocytes and DCs into the lung. We hypothesized
further that mDCs recruited into the lung show a strong antigen-
presenting capacity in contrast to recruited pDCs. Therefore,
the antigen-presenting capacity of DCs and monocytes was de-
termined in a co-culture with autologous T cells. Finally, the
level of cytokines and chemokines that could be involved in
allergic inflammation and LPS-triggered DC function was de-
termined in the bronchoalveolar lavage (BAL) fluid.
Some of the results of this study have been previously reported
at the ATS Conference 2006 in the form of an abstract (1).
METHODS
Study Design
Subjects with mild asthma who are allergic to house dust mite
underwent segmental challenges with allergen, endotoxin, and the
combination of both during a first bronchoscopy. During a second
bronchoscopy 24 hours later, bronchoalveolar lavages of the challenged
segments were performed. The cellular influx including monocytes,
mDCs, and pDCs, and the cytokine concentration in the BAL fluid,
was determined. For functional tests, a second segmental challenge
with allergen and endotoxin was done in a subgroup at least 8 weeks
after the preceding challenge. BALs were performed 24 hours later,
and monocytes, mDCs, and pDCs were isolated by a fluorescence-
activated cell sorter (FACS). After a co-culture with autologous T
cells, the T cell proliferation was determined.
Study Subjects
The study population consisted of 17 nonsmoking subjects (nine
women and eight men; mean age 28 6 5.2 yr) with mild persistent
allergic asthma (according to the asthma classification defined at the
GINA Report 2006, revised). The subjects only used b2-agonists if
required for relief of asthma symptoms. None of them was treated with
corticosteroids, sodium cromoglycate, theophylline, or leukotriene
modifiers within 4 weeks of the start of the study procedures. Subjects
with a past or present history of allergen immunotherapy were ex-
cluded. Each one had an AHR to methacholine (PC20 [provocative
concentration] , 8 mg/ml) determined as previously described (26) and
a positive airway response to an incremental inhaled allergen challenge
with Dermatophagiodes pteronyssinus (ALK-Scherax, Wedel, Germany).
The response was considered positive if the subject’s FEV1 decreased by at
least 20% after inhalation of up to a cumulative dose of 700 SQE house
dust mite allergen. All subjects had elevated serum IgE levels (. 100 IU/
ml), but otherwise normal laboratory test findings and no infections of the
respiratory tract during the last 4 weeks before the beginning of the study.
Females had to have a negative pregnancy test result before the start of the
study procedures. The Hannover Medical School ethics committee
approved the study protocol. Each subject signed a written informed
consent document before being included in the study.
Dosage and Preparation of Challenge Substances
To determine the allergen dose for the segmental instillation, a skin-
prick test with a dilution series of the allergen extract in saline was
done as previously described (26). The allergen concentration that
elicited at least a 3-mm-diameter skin weal response was selected for
instillation (100–100.000 SQE diluted in 10 ml saline). Endotoxin
challenge was done with 2 ng/kg endotoxin according to the protocol
of O’Grady and coworkers (15). Endotoxin was prepared using
lyophilized Clinical Center Reference Endotoxin (CCRE; Escherichia
coli strain O:113) in a final volume of 10 ml sterile saline. The doses of
allergen and endotoxin instilled in the combination segment were
identical to those in the single challenge segments. They were dissolved
in a final volume of 10 ml sterile saline.
To exclude endotoxin contamination of the allergen extract and to
verify the batch status of the CCRE, vials were reconstituted in sterile
saline and endotoxin activity was determined by an accredited refer-
ence laboratory using a quantitative kinetic analysis according to
European and United States Pharmacopoeia (Ph. Eur./USP) guide-
lines. The allergen extract showed very low endotoxin levels of 0.059
EU/ml for the highest allergen dose of 100.000 SQE. The endotoxin
activity of the CCRE was in high accordance with the labeled
specification.
Bronchoscopy
After premedication (inhalation of 200 mg salbutamol, atropine 0.5 mg
subcutaneously, and midazolam 0.05–0.1 mg/kg intravenously) and
local anesthesia with topical lidocaine, bronchoscopy was conducted
according to a standard protocol (27), which is consistent with in-
ternational recommendations for investigational bronchoscopies (28).
During the first bronchoscopy, the bronchoscope (BF 160 P; Olympus
Optical, Tokyo, Japan) was placed into one segment of the left lower
lobe in wedge position for a baseline BAL with 6 3 20 ml saline
solution (378C). The first aliquot was aspirated separately and dis-
carded. Next, 10 ml saline solution was instilled into a segment of the
left upper lobe bronchus as a control challenge. Allergen solution was
instilled in a segment of the lingular bronchus. The bronchoscope was
then passed into the right upper lobe and endotoxin solution was
segmentally instilled. Finally, a combination of allergen and endotoxin
was instilled in a segment of the right middle lobe. A new micro-
catheter (Vygon, Aachen, Germany) was used for each instillation.
After 24 hours, a second bronchoscopy was performed under identical
premedication. During this bronchoscopy, a BAL as described for
baseline was done in each challenged segment.
In five subjects, a third bronchoscopy was performed with the
instillation of allergen and endotoxin into a segment of the right middle
lobe under identical conditions at least 8 weeks after the second
bronchoscopy. During a fourth bronchoscopy 24 hours later, a BAL
was performed in the challenged segment.
Processing and Staining of BAL Cells
BAL fluid samples were processed as previously described (27).
Briefly, BAL fluid was filtered through a 100-mm filter and centrifuged.
The supernatant was stored at 2808C. The total nucleated cell count
was determined using a Neubauer hemocytometer. Differential cell
counts were done using Diff-Quick staining (Dade Behring Inc.,
Marburg, Germany) of cytospin slides and by counting 400 cells per
slide.
For immunofluorescence labeling, 5 3 105 BAL cells were used for
each test. Cells were incubated for 30 minutes at 48C with monoclonal
antibodies or isotype controls according to the manufacturer’s recom-
mendations (see below). The samples were lysed, fixed (Versa Lyse
Lysing solution; Beckman Coulter, Krefeld, Germany), washed, resus-
pended in PBS, and kept on ice until flow cytometric analysis. Using
a Cytomics FC 500 cytometer (Beckman Coulter), the data of 104 cells
were recorded and the surface marker expression analyzed using
Cytomics RXP software (Beckman Coulter).
Identification of Alveolar Monocytes and DC Subsets
Alveolar monocytes were differentiated from other BAL cells (alve-
olar macrophages, neutrophils, and eosinophils) by high expression of
CD14 and specific properties in size, granularity, and autofluorescence
as previously described (27). The identification of alveolar DC subsets
was based on two different three-color-assays (IOTest ‘‘myeloid sub-
set’’ [CD14/16-FITC, CD85k-PE, CD33-PC5] and IOTest ‘‘plasmacy-
toid subset’’ [CD14/16-FITC, CD85k-PE, CD123-PC5]: Immunotech,
Marseille, France). DCs were differentiated from monocytes and
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macrophages based on the expression of ILT3 (CD85k) (20, 29), which
is selectively expressed on monocytes, macrophages, and DCs, and the
co-expression of the interleukin-3 receptor (CD123) or CD33 as well as
a weak expression of CD14/CD16. pDCs were defined as cells with co-
expression of ILT3 and CD123, whereas mDCs were defined by cells
co-expressing ILT3 and CD33. A FACS plot is shown in Figure 1A to
demonstrate the gating strategy. According to the manufacturer’s in-
formation, mDCs and pDCs identified with this methodology have shown
an excellent correlation (r2 . 0.95) to the classical definition markers of
DC subsets (lineage-negative/HLA-DR1/CD11c1 for mDCs and lineage-
negative/HLA-DR1/CD1231 for pDCs, respectively). For the detection
of co-stimulatory molecules on DCs, BAL cells were additionally in-
cubated with biotinylated antibodies against HLA-DR (BD Biosciences,
Heidelberg, Germany), CD80 (Serotec, Düsseldorf, Germany), and
CD209 (Natutec, Frankfurt, Germany) according to the manufacturer’s
recommendations. In a second step, the cells were incubated with PE-CY-
7–labeled Streptavidin (Caltag, Hamburg, Germany).
Isolation of Alveolar Monocytes and DC Subsets by Activated
Cell Sorting
In a subsequent part of the study, monocytes and DC subsets obtained
during the fourth bronchoscopy were isolated using a FACSAria cell
sorter (BD Biosciences). Since the sorting experiments were done at
a time point when additional human pulmonary DC markers had been
described by Demedts and colleagues (19), a combination of the above-
described identification strategy with additional DC markers (BDCA-1;
BDCA-2) was used. The DC subsets were identified by a six-color staining
(BDCA-1-FITC, BDCA-2-PE, CD123-APC [Miltenyi Biotec, Bergisch
Gladbach, Germany], CD33-PerCPCy5.5, CD14-APC-Cy7 [BD Bio-
sciences], CD16-PE-Cy7 [Immunotech Beckman Coulter]), where pDCs
were defined as cells with co-expression of BDCA-2 and CD123, and
mDCs as cells co-expressing BDCA-1 and CD33. Both subpopulations of
DCs had to show a dim expression of CD14/CD16 because it has been
demonstrated that CD14/CD16 are expressed on DC precursors (30, 31).
This strategy is in accordance with the identification of DC subsets in the
human lavage by Bratke and coworkers (32) Monocytes were isolated by
their strong co-expression of CD14 and CD33. The different populations
were simultaneously sorted directly into continuously cooled (48C) non-
adherent tubes filled with culture medium.
Mixed Lymphocyte Cultures
Autologous T cells were isolated from subjects using anticoagulated
peripheral blood, Lymphoprep (Axis Shield PoC, Oslo, Norway) and
a T cell negative isolation kit with supraparamagnetic beads (Dynal
Biotech ASA, Oslo, Norway). Nonactivated T cells were isolated by
depleting non–T cells with a monoclonal antibody mix (CD14, CD16,
HLA-DR, CD56, and CD235a). For mixed lymphocyte cultures, 3 3
104 sorted alveolar cells (monocytes, mDCs, and pDCs) were co-
cultured with 1 3 105 autologous T cells for 5 to 7 days at 378C in
round-bottom 96-well plates (duplicate or triplicate) in 200 ml RPMI
1640 (with 10% FCS, penicillin, and streptomycin; Cambrex, Tauf-
kirchen, Germany). Cells were pulsed with 3.7 beq 3H-thymidine for 16 h
before harvest. Cell proliferation was assessed by scintillation using
a Topcount liquid scintillation counter (PerkinElmer, Rodgau, Germany).
Biochemical Analysis of BAL Fluid
The concentration of LPS-binding protein (LBP) in the BAL fluid was
determined by enzyme-linked immunosorbent assay (ELISA) (HBT,
Uden, The Netherlands). Furthermore, the concentrations of 30 cytokines
Figure 1. (A) Gating strategy
for identification of pulmonary
dendritic cell (DC) subsets.
Myeloid DCs (mDCs) were
identified as small cells with
low granularity (Gate A) co-
expressing CD33 and ILT3
(Gate B) and further differenti-
ated from monocytes by a dim
to negative expression of
CD14/16 (Gate C). Plasmacy-
toid DCs (pDCs) were identi-
fied as small cells with low
granularity (Gate A) expressing
CD123 and further identified
by expression of ILT3 (Gate D),
with a dim to negative expres-
sion of CD14/16 (Gate E). (B)
Expression of HLA-DR, and the
co-stimulatory molecules
CD86 and CD209, on subsets
of pulmonary DCs. Histograms
display the expression of sur-
face molecules on mDCs (blue)
compared with pDCs (red) and
the corresponding isotype
control (gray).
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and chemokines were determined simultaneously with a multiplex assay
kit (Lincoplex; Linco Research, Inc., St. Charles, MO) with premixed
antibody-coated microsphere beads using a Luminex100 (Luminex Cor-
poration, Austin, TX) according to the manufacturer’s recommendations.
Statistical Analysis
An overparameterized model as described in General Linear Models
(33) was used for the statistical analysis. The model itself was a mixed
model combining the fixed treatment effect and the random effect of
the patients (34). In the main effect analysis, all data samples (control,
allergen, endotoxin, and allergen1endotoxin) were used for the anal-
ysis. For each endpoint the paired post hoc analysis was performed
using a Tukey-Kramer HSD test to adjust for multiplicity (35). In all
analyses values of P , 0.05 were considered to be significant for both
tests. The statistical analysis was performed using STATISTICA for
Windows Version 7.1 (StatSoft, Inc., Hamburg, Germany).
RESULTS
Safety of the Procedures
After the incremental allergen inhalation, most of the subject
showed a late phase reaction 4 to 6 hours after the allergen
inhalation. Five subjects required treatment with inhaled ste-
roids and two subjects with oral prednisolone. The bronchos-
copies with the segmental challenges were well tolerated by
most of the patients. One subject was excluded from the study
after a complete atrioventricular block for 20 seconds after
administration of atropine (0.5 mg, subcutaneously) before the
first bronchoscopy. Another subject with a high AHR required
intravenous treatment with 125 mg prednisolone after the
second bronchoscopy. Furthermore, one subject was excluded
from the rest of the study due to an elevated number of lym-
phocytes in the baseline lavage.
Cellular Inflammatory Response to Allergen and Endotoxin
in the BAL
To investigate the effect of endotoxin on the allergic inflamma-
tion, we determined the absolute cell numbers of different cell
populations in the BAL fluid after challenges with saline,
allergen, endotoxin, and the combination of both (shown in
Figure 2). When all challenges were combined for the analysis
of the main effects, allergen had a significant effect on total
BAL cells and the numbers of lymphocytes, eosinophils, pDCs,
and mDCs, whereas endotoxin had an effect on total cells and
the numbers of lymphocytes, neutrophils, macrophages, mono-
cytes, pDCs, and mDCs. When the cellular response to allergen
was compared in the paired post hoc analysis to the response to
the combination of allergen with endotoxin, there was an
increase in the number of total cells, lymphocytes, neutrophils,
eosinophils, monocytes, and mDCs (post hoc analysis).
When surface marker expression on DC subsets was ana-
lyzed, there was a higher expression of HLA-DR and the co-
stimulatory molecules CD86 and CD209 on mDCs compared
with pDCs (see Figure 1B).
Capacity of DCs and Alveolar Monocytes to Induce
T Cell Proliferation
For functional characterization of the newly immigrated DCs,
alveolar monocytes and DC subsets (mDCs, pDCs) were iso-
lated after segmental provocation with allergen and endotoxin
from the BAL fluid and co-cultured with autologous T cells for
5 to 7 days. The capacity of mDCs to induce T cell proliferation
was significantly higher compared with monocytes and pDCs
and comparable to the mitogen control (Figure 3). The presence
of house dust mite allergen during the co-culture did not change
the T cell proliferation (data not shown).
Cytokine and Chemokine Levels in BAL Fluid in Response to
Allergen and Endotoxin
The concentration of LBP in the BAL fluid after the different
challenges determined by ELISA is shown in Figure 4. The
results of cytokines and chemokines determined with a multi-
plex assay kit are shown in Table E1 in the online supplement.
When all challenges were combined for the analysis of the main
effects, allergen had an effect on IL-1RA, IL-5, IL-6, IL-8, IL-13,
macrophage inflammatory protein (MIP)-1b, sCD40L, and tu-
mor necrosis factor (TNF)-a and endotoxin had an effect on IL-
1a, IL-1RA, IL-6, IP-10, MIP-1b, sCD40L, granulocyte colony-
stimulating factor, and TNF-a. When the challenge with allergen
was compared in the paired post hoc analysis to the combined
challenge, there was a significant increase in the concentration of
LBP, IL-1a, IL-6, and TNF-a in the BAL fluid. The concentra-
tion of IL-1b, IL-4, IL12p40, IL-12p70, IL-15, IL-17, vascular
endothelial growth factor, epidermal growth factor, MIP-1a,
interferon-g, and transforming growth factor-a was under the
detection limit and is not listed.
DISCUSSION
It is well established from epidemiologic studies that the
prevalence and the severity of asthma are dependent on the
environmental concentration of endotoxin (7, 8). Furthermore,
experimental studies have demonstrated a deterioration in lung
function and an increase in AHR when patients with asthma are
exposed to endotoxin (9, 10, 14, 36). Despite this well-described
endotoxin effect on asthma, there is hardly any information on
the underlying immunologic mechanism in the lung. Therefore,
the aim of this study was to elucidate the effect a controlled
endotoxin challenge had on the allergen-induced airway in-
flammation in patients with asthma.
When the cellular response to allergen alone was compared
with the response to the combination of allergen with endo-
toxin, there was an increase in the number of lymphocytes,
neutrophils, and eosinophils. Furthermore, the number of
monocytes and mDCs, but not the number of pDCs, increased
in the airways. When alveolar monocytes and DCs were isolated
after challenge with allergen plus endotoxin, mDCs demon-
strated the strongest T cell proliferation–inducing capacity.
While the enhancing effect of endotoxin on the eosinophilic
response in individuals with allergic asthma has already been
described in a preliminary report in sputum (37), our data
demonstrate for the first time that endotoxin augments the
influx of functionally highly active mDCs into the airways of
patients with asthma.
Several studies suggest that DCs play a crucial role in allergic
inflammation (38, 39). Animal studies have shown an increased
number of mDCs in the airways of sensitized and challenged
mice during the acute phase (40). The depletion of mDCs at the
time of allergen challenge eliminated airway inflammation and
AHR (40). The intratracheal instillation of mDCs restored the
response to allergen. Furthermore, in a chronic asthma model
the intratracheal instillation of bone marrow–derived mDCs
restored the reduced AHR and airway eosinophilia (23). While
this suggests that mDCs play a key role in inducing and
maintaining an adaptive immune response to allergens in the
lung, pDCs have been identified as important cells that prevent
asthmatic reactions to inhaled antigen by the induction of
tolerance (17, 24, 25).
In human asthma, a rapid DC recruitment to the bronchial
mucosa has been observed in response to local allergen challenge
(41). However, there is uncertainty whether the concept of
proallergic mDCs and antiallergic pDCs seen in animals is also
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true in humans. In the peripheral blood of asthma patients
a significantly higher number of pDCs in relation to mDCs was
found compared with normal subjects (42). Consistent with our
findings, Bratke and coworkers (32) recently showed that both
mDCs and pDCs accumulate in BAL fluid in patients with allergic
asthma after segmental allergen challenge. However, there are no
data on functional properties of these cells available in asthma.
We investigated the additional effect of endotoxin on the
DC accumulation in the lung and demonstrated that only
increased numbers of mDCs, but not pDCs, enter the airways.
Therefore, mDCs seem to play a prominent role at least in the
enhancement of the allergic inflammation due to endotoxin. We
also showed that functional properties of DC subsets are largely
different and that mDCs but not pDCs induce T cell proliferation.
This is in accordance with data from Demedts and colleagues
(19), who showed in human tissue samples from patients with
lung cancer that pulmonary mDCs are much stronger inducers
of T cell proliferation than pDCs (43). Although it would be
expected that the addition of HDM to the mDC/T cell co-cultures
would increase T cell proliferation, we did not observe this effect.
A possible explanation could be that the DCs were activated
in vivo and, thus, could not present additional allergen effectively
in vitro. The inability of pDCs to induce proliferation might be
explained by their lack of co-stimulatory molecules. We have
determined exemplarily the expression of activation markers on
alveolar DCs and found a lower expression of HLA-DR and
CD86 on pDCs compared with mDCs. This is in accordance with
data from Demedts and coworkers (19) and Masten and col-
leagues (21). Furthermore, the co-stimulatory molecule DC-
SIGN (CD209), which plays an important role in DC antigen
presentation to T cells (44), is highly expressed on mDCs but not
on pDCs.
Figure 2. Numbers of (A) total cells, (B)
lymphocytes, (C ) neutrophils, (D) eosinophils,
(E ) macrophages, (F ) monocytes, (G) pDCs,
and (H ) mDCs in bronchoalveolar lavage fluid
24 hours after instillation with saline, allergen,
endotoxin, and the combination of aller-
gen1endotoxin (— Mean; *P , 0.05; **P ,
0.01; ***P , 0.005).
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In the presence of so-called danger signals like endotoxin,
DCs undergo changes toward maturation and activation with
a high expression of co-stimulatory molecules (45). Toll-like
receptors (TLRs), which recognize these ‘‘pathogen-associated
molecular patterns,’’ have been described on human DCs: TLR-
2 and TLR-4 are expressed on mDCs, whereas pDCs express
TLR-7 (21, 43). Therefore, endotoxin can bind and activate
mDCs via TLR-4, resulting in an increased influx of mDCs with
a high ability to induce T cell proliferation into the airways.
The role of monocytes in asthma, and particularly in endo-
toxin-enhanced asthma, is poorly understood. In individuals with
asthma the recruitment of monocytes into the airways has been
described after repeated allergen challenges (46, 47). In our
study we found an even higher number of CD141 monocytes in
the lavage fluid when LPS was given in addition to allergen.
Therefore, LPS enhances the monocyte recruitment into the lung
in allergic asthma. LBP levels were investigated in BAL fluid
because LBP enhances the binding of LPS to the endotoxin
receptor CD14 on monocytes and LBP is one of the critical
molecules regulating the acute airway response to LPS (48).
While others have already shown increased levels of LBP after
allergen challenge (49), we demonstrate here an additional effect
after LPS exposure. Therefore, the presence of LPS further
enhances the binding of LPS to CD14-expressing cells.
We saw increased levels of typical monocyte/DC-derived
cytokines like IL-1a, IL-6, and TNF-a in the BAL fluid after
allergen plus endotoxin challenge compared with allergen
challenge alone. Interestingly, van Haarst and coworkers (50)
described low autofluorescent monocytes in BAL fluid with
a low T cell stimulatory capability which produced high levels of
IL-1, IL-6, and TNF-a when they were isolated and stimulated
with endotoxin. Therefore, monocytes recruited to the lung
might be important sources of pro-inflammatory cytokines,
which play a significant role in the allergic inflammation.
In conclusion, we have shown in patients with bronchial
asthma that endotoxin induces an enhanced allergic inflamma-
tory response in the lung with an enhanced influx of monocytes
and highly potent antigen-presenting mDCs into the alveolar
space. These data might provide a mechanism by which
endotoxin increases the prevalence and severity of asthma
shown in epidemiologic and clinical studies.
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